Solid Tumor

Exicure Inc (NASDAQ: XCUR) has reported interim results from Phase 1b/2 trial evaluating cavrotolimod (AST-008) in patients with advanced or metastatic solid tumors refractory to anti-PD-(L)1 therapy.  The trial is assessing cavrotolimod in combination with Merck & Co...

Atreca Inc (NASDAQ: BCEL) stock is hovering at a 52-week low after it announced initial data from the dose-escalation portion of its ongoing Phase 1b trial evaluating ATRC-101 in select solid tumor types. Twenty-six participants were dosed. Eight of the 20 participants (40%)...

Adagene Inc (NASDAQ: ADAG) has entered into a clinical trial collaboration and supply agreement with Merck & Co Inc (NYSE: MRK).  The agreement includes two clinical studies to evaluate Adagene's anti-CTLA-4 monoclonal antibody (mAb) candidates, ADG116 and...

BioNTech SE (NASDAQ: BNTX) is buying a cell therapy R&D platform plus a manufacturing site from Gilead Science Inc's (NASDAQ: GILD) Kite subsidiary. The deal gives BioNTech Kite's R&D IP for its personalized solid tumor neoantigen T cell receptor (TCR) work...

Genocea Biosciences Inc (NASDAQ: GNCA) has dosed the first patient in its TiTAN Phase 1/2a study, evaluating its GEN-011 therapy in solid tumors. TiTAN is an open-label, multi-center trial evaluating the safety, tolerability, T cell persistence, proliferation, and clinical efficacy...

Cellectar Biosciences Inc (NASDAQ: CLRB) has collaborated with LegoChemBio to develop and commercialize phospholipid drug conjugates (PDCs). Under the agreement, the two companies have the option to jointly develop three new small molecule PDCs utilizing Cellectar's drug...

NextCure Inc (NASDAQ: NXTC) has initiated the clinical trial of its third product candidate, NC762, a humanized B7-H4 monoclonal antibody. The Phase 1 dose-escalation portion of this Phase 1/2 open-label trial will evaluate the safety and tolerability of NC762 in patients with...

Immutep (NASDAQ: IMMP) will begin a Phase 1 trial to evaluate its lead product candidate, eftilagimod alpha (efti or IMP321), in conjunction with chemotherapy and anti-PD-1 therapy. The trial, named INSIGHT-003, will be carried out at the Institute of Clinical Cancer Research IKF at...

Eisai Co Ltd (OTC: ESALY) and Bristol-Myers Squibb Co (NYSE: BMY) have entered into an exclusive global strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody-drug conjugate (ADC). Bristol Myers will pay $650 million,...

Lineage Cell Therapeutics Inc (NYSE: LCTX) has granted an exclusive option to Amasa Therapeutics Inc to acquire an exclusive, royalty-bearing license to use its HyStem technology to develop and commercialize therapies for local treatment of solid tumors under pre-negotiated terms....

Cellectis SA (NASDAQ: CLLS) has announced four new preclinical UCART product candidates targeting solid tumors - UCART20x22; the first allogeneic bi-specific CAR-T cell targeting B-cell malignancies, and three additional product candidates for solid tumors UCARTMESO (mesothelin),...

Fusion Pharmaceuticals Inc (NASDAQ: FUSN) has announced preliminary Phase 1 data from the single-dose portion of the study evaluating FPI-1434 in patients with IGF-1R expressing solid tumors. Data were shared at the Society of Nuclear Medicine and Molecular Imaging Virtual Annual...

Compugen Ltd (NASDAQ: CGEN) has announced updated data from its Phase 1 dose-escalation and expansion study of COM701 as a monotherapy and in a dose-escalation combination study with Bristol-Myers Squibb & Co's (NYSE: BMS) Opdivo (nivolumab). Data were presented at...

Harpoon Therapeutics Inc (NASDAQ: HARP) provides updated interim data from the ongoing dose-escalation portion of the Phase 1/2a trial for HPN424 in patients with metastatic castration-resistant prostate cancer (mCRPC). Data were presented at the American Society of Clinical...

Oric Pharmaceuticals Inc (NASDAQ: ORIC) has announced initial data from an ongoing Phase 1b study evaluating ORIC-101 in combination with nab-paclitaxel, in advanced solid tumors. Data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. As of the...